Indian manufacturer new recipient of mRNA technology through the mRNA technology transfer hub

Spread the Message

Read Time:40 Second

31 March 2022 WHO News release

After reviewing a number of proposals from India, WHO’s Product Development for Vaccines Advisory Committee (PDVAC) today selected the company BiologicalE (Bio E) as a recipient of mRNA technology from the WHO technology transfer hub.

Bio E already manufactures a number of critical vaccines, including Corbevax, a second-generation vaccine for COVID-19.

WHO and partners will work with the Indian government and Bio E to develop a roadmap and put in place the necessary training and support so that the company can start producing mRNA vaccines as soon as possible.

Primarily set up to address the COVID-19 emergency, the hub has the potential to expand manufacturing capacity for other products as well, including treatments, and target other priorities such as malaria, HIV and cancer.

About Post Author

Dr Akshay Minhas

MD (Community Medicine) PGDGARD (GIS) Assistant Professor Dr. Rajendra Prasad Government Medical College (DR.RPGMC), Tanda Kangra, Himachal Pradesh, India

[email protected]

https://healthandfamiliy.in